RESEARCH PROJECTS
National – ONGOING
| Sl. No | Principal Investigator | Co-Principal Investigator | Title of the Project | Funding Agency | Duration (From-To) | Clinical Trial Registration Details if any | Status of the project |
| 1 | Dr. Ravi Sarvi | Research Project: -“Evaluation of mir-124-3p & mir-337 as prognotic biomarkers of lupus nephritis with clinical assessement” | KAHER’s Research and Development Cell | 1 Year | |||
| 2 | Dr M S Karishetti (Khanpet) | “Therapeutic Drug Monitoring (TDM) Of Meropenem to Detect an Effective Plasma Drug Concentration to Prevent Antimicrobioal Resistance(AMR) in Chronic Renal Failure(CRF) Patients.” | KAHER’s Research and Development Cell | 1 Year | |||
| 1 | Dr. Ritesh Vernekar | Nil | Clinical Trial-OMS-721-IGA001 A Randomised, Double-blind, Placebo-controlled, Phase 3 study of the safety and efficiacy of OMS721 in patient with IgA Nephropathy. | Omeros Research | 36 Months | ||
| 2 | Dr. Ritesh Vernekar | Nil | A Phase 2b/3, Multi-part, Randomized, double-Blinded, Placebo-Controllrd stiudy to evalute the efficacy and safety of Atacicept in subject with IgA Nephropathy(IgAN) | MEDPACE | 6 Months | ||
| 3 | Dr. Ritesh Vernekar | Nil | A Double-Blind, Randomixed,Placebo-controlled phase 2 clonical trial a evalute safty and efficacy of US-APR2020 in subject with chronic Kidney Diease stage IV | CRO:Lifesan clinical Resarch, a division of Centaur Pharmaceuticals Pvt.Ltd | 6 Months | ||
| 4 | Dr. Ritesh Vernekar | Nil | A Phase 3 Superiority study Comparing the safety and Efficacy of SNP-ACTH(1-39)Gel compared to Rituximab and FDA approved biosimilar in Adults with primary Membranous Nephropathy (PMN) in a two -phase Adaptive trial design | Cliantha Research | 6 Months | ||
| 5 | Dr. Ritesh Vernekar | Nil | A parallel-goup treatment , Phase 2, double-blind,three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in paticipants with chronic kidney diease and type 2 diabetes | Swiss BioQuant AG | 6 Months | ||
| 6 | Dr. Ritesh Vernekar | Nil | A Phase 2b, Randomized,Controlled double blind,Multicenter study comparing the efficacy and safety of Zetomipzomib(KZR-616)30 mg or 60 n with Placebo in patients with active lupus Nephritis | Nil | 7 Months | ||
| 7 | Dr. Ritesh Vernekar | Nil | A phase 3,International, Radomised, Double-blind, Placebo-controlled Study to Evaluate the effect of Sodium Zirconium Cyclosilicate on Choronic Kidney disease(CKD) Progression in Participants with CKD and Hyperkalaemia or at Risk of Hyperkalaemia(STABILIZE-CKD) | Astrazeneca Pharma India Limited | 6 Months | ||